Clinical Trials Logo

Filter by:
NCT ID: NCT05430815 Active, not recruiting - Maternal Death Clinical Trials

Improving Women's Health Through Coordinated Postpartum Planning

Start date: August 8, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to design, implement, and evaluate a holistic postpartum women's health care system for women who have cardiovascular risk factors for severe maternal morbidity (SMM) including chronic hypertension, chronic diabetes, gestational diabetes, pre-pregnancy obesity, or a hypertensive disorder of pregnancy (HDP) which includes gestational hypertension or preeclampsia. The researchers will use a sequential mixed methods design. First, the researchers will conduct in-depth interviews with women who have given birth in the prior year to characterize barriers and facilitators to accessing postpartum care. The information from these interviews will be used to inform the design of a postpartum care system. Next, the researchers will conduct a pragmatic randomized trial to test the effectiveness of the system on postpartum care engagement versus standard of care.

NCT ID: NCT05430204 Active, not recruiting - Clinical trials for Gestational Diabetes

Continuous Glucose Monitoring for Screening for Diabetes in Pregnancy

Start date: March 7, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether Continuous glucose monitoring (CGM) for diagnosis of gestational diabetes mellitus (GDM) improves maternal and neonatal outcomes related to GDM and to evaluate whether CGM for GDM diagnosis reduces the health system costs for mother-infant dyads compared to usual care

NCT ID: NCT05430113 Active, not recruiting - Clinical trials for Spinal Muscular Atrophy Type 3

Spinal Cord Stimulation in Spinal Muscular Atrophy

SCSinSMA
Start date: April 5, 2022
Phase: N/A
Study type: Interventional

Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor deficits in people with type 3 or 4 spinal muscular atrophy (SMA). The investigators will enroll up to six subjects with Type 3 or 4 SMA aged 16 or older that show quantifiable motor deficits of the legs but are able to stand independently. The investigators will then implant the subjects with percutaneous, bilateral, linear spinal leads near the lumbar spinal cord for a period of up to 29 days. Although these leads are not optimized for motor function but rather for their clinically approved indication of treating pain, the investigators believe they provide a safe technology enabling our team to perform scientific measurement necessary to evaluate potential for effects of SCS in motor paralysis with SMA. After the end of the study, the leads will be explanted.

NCT ID: NCT05429372 Active, not recruiting - Clinical trials for Muscular Dystrophy, Duchenne

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Start date: August 8, 2022
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study

NCT ID: NCT05427279 Active, not recruiting - Clinical trials for Effect of Food Supplement

Effects of Vitamin C Enriched Hydrolyzed Collagen, PrimaCollâ„¢, Whey Protein, or Placebo on Collagen Synthesis

Start date: October 5, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of repeated dosing vitamin C enriched hydrolyzed collagen (HC) over a 24hr period, compared to PrimaCollâ„¢ (PC), whey protein (WP) and placebo (PL), with prescribed exercise on collagen synthesis. To achieve this, participants will consume a supplemental dose of HC (20g with 50mg vitamin C), PC (20g with 50mg vitamin C), whey protein (20g whey isolate with 50mg vitamin C) or a placebo (20g maltodextrin with 50mg vitamin C) 1hr prior to an exercise bout (6 minutes of jump rope), this will be repeated three times over a 24h period. The amount of collagen protein synthesized will be indirectly measured by measuring pro-collagen type I N-terminal propeptide (PINP) in the serum before and 4hrs after the last exercise bout.

NCT ID: NCT05426460 Active, not recruiting - Smoking, Cigarette Clinical Trials

AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior

Start date: April 29, 2022
Phase: N/A
Study type: Interventional

Smokers are highly reactive to smoking-related stimuli and report that this cue reactivity (CR) is a major obstacle to quitting. To date, no pharmacologic methods attenuate CR, and attempts to diminish it with traditional cue exposure treatment (CET) have not proven effective. The proposed study will test a highly novel cue-based smoking treatment adjunct combining an Approach/Avoidance Task (AAT) with brain stimulation via tDCS applied to the dorsolateral prefrontal cortex (dlPFC) during personalized multi-cue exposure; the goal of which is to discover an effective means of reducing cue reactivity and daily smoking, and increasing intent and confidence to quit, among high treatment-interest smokers.

NCT ID: NCT05426356 Active, not recruiting - Osteoporosis Clinical Trials

Sacral Fracture Fusion/Fixation for Rapid Rehabilitation

SAFFRON
Start date: September 18, 2022
Phase: N/A
Study type: Interventional

To determine the safety and efficacy of concomitant sacral fracture fixation and sacroiliac (SI) joint fusion vs. non-surgical management for patients with debilitating sacral fragility or insufficiency fractures

NCT ID: NCT05425745 Active, not recruiting - Clinical trials for Hypercholesterolemia

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

BROOKLYN
Start date: July 25, 2022
Phase: Phase 3
Study type: Interventional

This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia (HeFH).

NCT ID: NCT05425446 Active, not recruiting - Celiac Disease Clinical Trials

Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

Start date: September 19, 2022
Phase: Phase 1
Study type: Interventional

This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.

NCT ID: NCT05425316 Active, not recruiting - Clinical trials for Hepatic Encephalopathy

Speech in Hepatic Encephalopathy (HE)

Start date: October 5, 2021
Phase:
Study type: Observational

This is an observational study that will test the clinical significance of speech features in patients with cirrhosis. It aims to assess if speech is associated with cognitive function at baseline, if speech predicts changes in cognition, and if speech predicts future events of hepatic encephalopathy (cirrhosis-related confusion), as well as to assess the dynamics of speech over time, especially with episodes of overt hepatic encephalopathy (OHE) and treatment interventions.